MARKET

APLS

APLS

Apellis Pharmace
NASDAQ
21.93
-0.38
-1.70%
Opening 13:20 02/12 EST
OPEN
22.23
PREV CLOSE
22.31
HIGH
22.38
LOW
21.72
VOLUME
248.83K
TURNOVER
--
52 WEEK HIGH
30.48
52 WEEK LOW
16.10
MARKET CAP
2.77B
P/E (TTM)
73.84
1D
5D
1M
3M
1Y
5Y
1D
Is It Time To Reassess Apellis Pharmaceuticals (APLS) After The Recent Share Price Slide
Simply Wall St · 23h ago
APLS Makes Notable Cross Below Critical Moving Average
NASDAQ · 1d ago
Apellis Pharmaceuticals Inc. to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results
Reuters · 2d ago
Apellis Pharmaceuticals Inc. kündigt Finanz-Update an
Reuters · 2d ago
Short Report: VNET Group short interest at 4-month high
TipRanks · 3d ago
Weekly Report: what happened at APLS last week (0202-0206)?
Weekly Report · 3d ago
Broad S&P Index Inclusion Might Change The Case For Investing In Apellis Pharmaceuticals (APLS)
Simply Wall St · 5d ago
A Look At Apellis Pharmaceuticals (APLS) Valuation After Recent S&P Index Additions
Simply Wall St · 6d ago
More
About APLS
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan) is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and the United Kingdom.

Webull offers Apellis Pharmaceuticals Inc stock information, including NASDAQ: APLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APLS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APLS stock methods without spending real money on the virtual paper trading platform.